Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Unknown 2Completed 2Terminated 1Recruiting 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 413Carcinoma, Non-Small-Cell Lung 286Prostatic Neoplasms 208Neoplasms 204Neoplasm Metastasis 180Melanoma 164Multiple Myeloma 158Colorectal Neoplasms 158Leukemia, Myeloid, Acute 143Lung Neoplasms 132Leukemia 126Lymphoma 118Pancreatic Neoplasms 117Recurrence 111Ovarian Neoplasms 111Leukemia, Lymphocytic, Chronic, B-Cell 110Lymphoma, Non-Hodgkin 105Carcinoma, Renal Cell 104Brain Neoplasms 90Myelodysplastic Syndromes 88Precursor Cell Lymphoblastic Leukemia-Lymphoma 86Glioblastoma 85Lymphoma, Large B-Cell, Diffuse 80Lymphoma, Follicular 79Carcinoma, Hepatocellular 79Head and Neck Neoplasms 77Squamous Cell Carcinoma of Head and Neck 76Urinary Bladder Neoplasms 66Stomach Neoplasms 61Hodgkin Disease 60

Interventions

avasopasem manganese 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Esophagitis × Clear all
NCT04225026 2023-03-23

Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer

Galera Therapeutics, Inc.

Phase 2 Terminated
39 enrolled 12 charts

Esophagitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡